by Csequence | Aug 30, 2022 | Communications, Weekly Cannabis News
Weekly Cannabis News August 19th – August 26th, 2022 Low ∆9-Tetrahydrocannabinol (∆9-THC) Cannabis Oil for Fibromyalgia (FM) Treatment Study results showed that this cannabis extract was effective in reversing FM symptoms in a mouse model. Fibromyalgia (FM) is a...by Csequence | Aug 19, 2022 | Communications, Weekly Cannabis News
Weekly Cannabis News August 12th – August 19th, 2022 Post-Traumatic Stress Disorder (PTSD) & Cannabis Use During COVID-19 Individuals who reported an increase in cannabis consumption during the pandemic displayed worsening depressive symptoms, a new study...by Csequence | Aug 17, 2022 | Market Intelligence
Csequence is proud to announce the first part of our virtual expert panel series on the use of cannabis in fighting cancer. In July we heard from physicians who discussed their views on the topic, the data they have seen and the trials they are working on. This...by Csequence | Aug 11, 2022 | Communications, Weekly Cannabis News
Weekly Cannabis News August 5th – August 12th, 2022 Cannabis Use & COVID-19 Symptoms Severity COVID-19 cannabis consumers reported better clinical outcomes compared to non-consumers, suggesting the need for additional investigations. The novel severe acute...by Csequence | Aug 9, 2022 | Communications, Journal Club
Discussion around the effects of a cannabinoid receptor 1 antagonist on THC-induced vascular inflammation Please join us for a conversation about a study published in 2022 in the Journal Cell entitled: “Cannabinoid receptor 1 antagonist genistein...